Loading…

What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance

Defibrotide (DF) has received European Medicines Agency authorization to treat sinusoidal obstruction syndrome, an early complication after hematopoietic cell transplantation. DF has a recognized role as an endothelial protective agent, although its precise mechanism of action remains to be elucidat...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2016-03, Vol.127 (13), p.1719-1727
Main Authors: Palomo, Marta, Mir, Enrique, Rovira, Montse, Escolar, Ginés, Carreras, Enric, Diaz-Ricart, Maribel
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c463t-d162c24fe2c553e964b81ce31560982fa81a7c62a3a40e4b2728f19a310c94263
cites cdi_FETCH-LOGICAL-c463t-d162c24fe2c553e964b81ce31560982fa81a7c62a3a40e4b2728f19a310c94263
container_end_page 1727
container_issue 13
container_start_page 1719
container_title Blood
container_volume 127
creator Palomo, Marta
Mir, Enrique
Rovira, Montse
Escolar, Ginés
Carreras, Enric
Diaz-Ricart, Maribel
description Defibrotide (DF) has received European Medicines Agency authorization to treat sinusoidal obstruction syndrome, an early complication after hematopoietic cell transplantation. DF has a recognized role as an endothelial protective agent, although its precise mechanism of action remains to be elucidated. The aim of the present study was to investigate the interaction of DF with endothelial cells (ECs). A human hepatic EC line was exposed to different DF concentrations, previously labeled. Using inhibitory assays and flow cytometry techniques along with confocal microscopy, we explored: DF-EC interaction, endocytic pathways, and internalization kinetics. Moreover, we evaluated the potential role of adenosine receptors in DF-EC interaction and if DF effects on endothelium were dependent of its internalization. Confocal microscopy showed interaction of DF with EC membranes followed by internalization, though DF did not reach the cell nucleus even after 24 hours. Flow cytometry revealed concentration, temperature, and time dependent uptake of DF in 2 EC models but not in other cell types. Moreover, inhibitory assays indicated that entrance of DF into ECs occurs primarily through macropinocytosis. Our experimental approach did not show any evidence of the involvement of adenosine receptors in DF-EC interaction. The antiinflammatory and antioxidant properties of DF seem to be caused by the interaction of the drug with the cell membrane. Our findings contribute to a better understanding of the precise mechanisms of action of DF as a therapeutic and potential preventive agent on the endothelial damage underlying different pathologic situations. •Specific interaction of DF with EC membranes is followed by its internalization mainly through macropinocytic mechanisms.•DF attachment to the cell membrane is sufficient to perform its antiinflammatory and antioxidant effects on the endothelium.
doi_str_mv 10.1182/blood-2015-10-676114
format article
fullrecord <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4817313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120303049</els_id><sourcerecordid>S0006497120303049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-d162c24fe2c553e964b81ce31560982fa81a7c62a3a40e4b2728f19a310c94263</originalsourceid><addsrcrecordid>eNp9kMFO3DAQhi0EYpeFN6gqv0DAYztOcimqELSVVuIAVY-WY0923WbtlR0W9e1JWLqll55G84_-f2Y-Qj4AuwSo-VXbx-gKzqAsgBWqUgDyiMyh5HXBGGfHZM4YU4VsKpiRs5x_MgZS8PKUzLiqyrJi9Zz8-rE2A_WZrqIPKxoDbXF4RgzUYefbFAfvkJrgKAYXhzX23vTUYt_na_oQzDav45Bpwh2O-jinY0_zdhJjNwk-0RQ3Jlg8Jyed6TNevNUF-X53-3jztVjef_l283lZWKnEUDhQ3HLZIbdlKbBRsq3BooBSsabmnanBVFZxI4xkKFte8bqDxghgtpFciQX5tM_dPrUbdBbDkEyvt8lvTPqto_H630nwa72KOy1rqASIMUDuA2yKOSfsDl5geoKvX-HrCf4k7eGPto_v9x5Mf2j_PQzH73cek87W40jG-YR20C76_294AcXCmDE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance</title><source>ScienceDirect®</source><creator>Palomo, Marta ; Mir, Enrique ; Rovira, Montse ; Escolar, Ginés ; Carreras, Enric ; Diaz-Ricart, Maribel</creator><creatorcontrib>Palomo, Marta ; Mir, Enrique ; Rovira, Montse ; Escolar, Ginés ; Carreras, Enric ; Diaz-Ricart, Maribel</creatorcontrib><description>Defibrotide (DF) has received European Medicines Agency authorization to treat sinusoidal obstruction syndrome, an early complication after hematopoietic cell transplantation. DF has a recognized role as an endothelial protective agent, although its precise mechanism of action remains to be elucidated. The aim of the present study was to investigate the interaction of DF with endothelial cells (ECs). A human hepatic EC line was exposed to different DF concentrations, previously labeled. Using inhibitory assays and flow cytometry techniques along with confocal microscopy, we explored: DF-EC interaction, endocytic pathways, and internalization kinetics. Moreover, we evaluated the potential role of adenosine receptors in DF-EC interaction and if DF effects on endothelium were dependent of its internalization. Confocal microscopy showed interaction of DF with EC membranes followed by internalization, though DF did not reach the cell nucleus even after 24 hours. Flow cytometry revealed concentration, temperature, and time dependent uptake of DF in 2 EC models but not in other cell types. Moreover, inhibitory assays indicated that entrance of DF into ECs occurs primarily through macropinocytosis. Our experimental approach did not show any evidence of the involvement of adenosine receptors in DF-EC interaction. The antiinflammatory and antioxidant properties of DF seem to be caused by the interaction of the drug with the cell membrane. Our findings contribute to a better understanding of the precise mechanisms of action of DF as a therapeutic and potential preventive agent on the endothelial damage underlying different pathologic situations. •Specific interaction of DF with EC membranes is followed by its internalization mainly through macropinocytic mechanisms.•DF attachment to the cell membrane is sufficient to perform its antiinflammatory and antioxidant effects on the endothelium.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2015-10-676114</identifier><identifier>PMID: 26755708</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anti-Inflammatory Agents - pharmacokinetics ; Antioxidants - pharmacokinetics ; Cell Membrane - drug effects ; Cell Membrane - metabolism ; Cells, Cultured ; Dose-Response Relationship, Drug ; Human Umbilical Vein Endothelial Cells - drug effects ; Human Umbilical Vein Endothelial Cells - metabolism ; Humans ; Inflammation - pathology ; Inflammation - prevention &amp; control ; Nitric Oxide Synthase Type III - metabolism ; Pinocytosis - drug effects ; Polydeoxyribonucleotides - pharmacokinetics ; Temperature ; Time Factors ; Vascular Biology</subject><ispartof>Blood, 2016-03, Vol.127 (13), p.1719-1727</ispartof><rights>2016 American Society of Hematology</rights><rights>2016 by The American Society of Hematology.</rights><rights>2016 by The American Society of Hematology 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-d162c24fe2c553e964b81ce31560982fa81a7c62a3a40e4b2728f19a310c94263</citedby><cites>FETCH-LOGICAL-c463t-d162c24fe2c553e964b81ce31560982fa81a7c62a3a40e4b2728f19a310c94263</cites><orcidid>0000-0002-6658-0381 ; 0000-0002-3261-6577 ; 0000-0003-1122-0052</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497120303049$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3547,27922,27923,45778</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26755708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Palomo, Marta</creatorcontrib><creatorcontrib>Mir, Enrique</creatorcontrib><creatorcontrib>Rovira, Montse</creatorcontrib><creatorcontrib>Escolar, Ginés</creatorcontrib><creatorcontrib>Carreras, Enric</creatorcontrib><creatorcontrib>Diaz-Ricart, Maribel</creatorcontrib><title>What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance</title><title>Blood</title><addtitle>Blood</addtitle><description>Defibrotide (DF) has received European Medicines Agency authorization to treat sinusoidal obstruction syndrome, an early complication after hematopoietic cell transplantation. DF has a recognized role as an endothelial protective agent, although its precise mechanism of action remains to be elucidated. The aim of the present study was to investigate the interaction of DF with endothelial cells (ECs). A human hepatic EC line was exposed to different DF concentrations, previously labeled. Using inhibitory assays and flow cytometry techniques along with confocal microscopy, we explored: DF-EC interaction, endocytic pathways, and internalization kinetics. Moreover, we evaluated the potential role of adenosine receptors in DF-EC interaction and if DF effects on endothelium were dependent of its internalization. Confocal microscopy showed interaction of DF with EC membranes followed by internalization, though DF did not reach the cell nucleus even after 24 hours. Flow cytometry revealed concentration, temperature, and time dependent uptake of DF in 2 EC models but not in other cell types. Moreover, inhibitory assays indicated that entrance of DF into ECs occurs primarily through macropinocytosis. Our experimental approach did not show any evidence of the involvement of adenosine receptors in DF-EC interaction. The antiinflammatory and antioxidant properties of DF seem to be caused by the interaction of the drug with the cell membrane. Our findings contribute to a better understanding of the precise mechanisms of action of DF as a therapeutic and potential preventive agent on the endothelial damage underlying different pathologic situations. •Specific interaction of DF with EC membranes is followed by its internalization mainly through macropinocytic mechanisms.•DF attachment to the cell membrane is sufficient to perform its antiinflammatory and antioxidant effects on the endothelium.</description><subject>Anti-Inflammatory Agents - pharmacokinetics</subject><subject>Antioxidants - pharmacokinetics</subject><subject>Cell Membrane - drug effects</subject><subject>Cell Membrane - metabolism</subject><subject>Cells, Cultured</subject><subject>Dose-Response Relationship, Drug</subject><subject>Human Umbilical Vein Endothelial Cells - drug effects</subject><subject>Human Umbilical Vein Endothelial Cells - metabolism</subject><subject>Humans</subject><subject>Inflammation - pathology</subject><subject>Inflammation - prevention &amp; control</subject><subject>Nitric Oxide Synthase Type III - metabolism</subject><subject>Pinocytosis - drug effects</subject><subject>Polydeoxyribonucleotides - pharmacokinetics</subject><subject>Temperature</subject><subject>Time Factors</subject><subject>Vascular Biology</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9kMFO3DAQhi0EYpeFN6gqv0DAYztOcimqELSVVuIAVY-WY0923WbtlR0W9e1JWLqll55G84_-f2Y-Qj4AuwSo-VXbx-gKzqAsgBWqUgDyiMyh5HXBGGfHZM4YU4VsKpiRs5x_MgZS8PKUzLiqyrJi9Zz8-rE2A_WZrqIPKxoDbXF4RgzUYefbFAfvkJrgKAYXhzX23vTUYt_na_oQzDav45Bpwh2O-jinY0_zdhJjNwk-0RQ3Jlg8Jyed6TNevNUF-X53-3jztVjef_l283lZWKnEUDhQ3HLZIbdlKbBRsq3BooBSsabmnanBVFZxI4xkKFte8bqDxghgtpFciQX5tM_dPrUbdBbDkEyvt8lvTPqto_H630nwa72KOy1rqASIMUDuA2yKOSfsDl5geoKvX-HrCf4k7eGPto_v9x5Mf2j_PQzH73cek87W40jG-YR20C76_294AcXCmDE</recordid><startdate>20160331</startdate><enddate>20160331</enddate><creator>Palomo, Marta</creator><creator>Mir, Enrique</creator><creator>Rovira, Montse</creator><creator>Escolar, Ginés</creator><creator>Carreras, Enric</creator><creator>Diaz-Ricart, Maribel</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6658-0381</orcidid><orcidid>https://orcid.org/0000-0002-3261-6577</orcidid><orcidid>https://orcid.org/0000-0003-1122-0052</orcidid></search><sort><creationdate>20160331</creationdate><title>What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance</title><author>Palomo, Marta ; Mir, Enrique ; Rovira, Montse ; Escolar, Ginés ; Carreras, Enric ; Diaz-Ricart, Maribel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-d162c24fe2c553e964b81ce31560982fa81a7c62a3a40e4b2728f19a310c94263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anti-Inflammatory Agents - pharmacokinetics</topic><topic>Antioxidants - pharmacokinetics</topic><topic>Cell Membrane - drug effects</topic><topic>Cell Membrane - metabolism</topic><topic>Cells, Cultured</topic><topic>Dose-Response Relationship, Drug</topic><topic>Human Umbilical Vein Endothelial Cells - drug effects</topic><topic>Human Umbilical Vein Endothelial Cells - metabolism</topic><topic>Humans</topic><topic>Inflammation - pathology</topic><topic>Inflammation - prevention &amp; control</topic><topic>Nitric Oxide Synthase Type III - metabolism</topic><topic>Pinocytosis - drug effects</topic><topic>Polydeoxyribonucleotides - pharmacokinetics</topic><topic>Temperature</topic><topic>Time Factors</topic><topic>Vascular Biology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Palomo, Marta</creatorcontrib><creatorcontrib>Mir, Enrique</creatorcontrib><creatorcontrib>Rovira, Montse</creatorcontrib><creatorcontrib>Escolar, Ginés</creatorcontrib><creatorcontrib>Carreras, Enric</creatorcontrib><creatorcontrib>Diaz-Ricart, Maribel</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Palomo, Marta</au><au>Mir, Enrique</au><au>Rovira, Montse</au><au>Escolar, Ginés</au><au>Carreras, Enric</au><au>Diaz-Ricart, Maribel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2016-03-31</date><risdate>2016</risdate><volume>127</volume><issue>13</issue><spage>1719</spage><epage>1727</epage><pages>1719-1727</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Defibrotide (DF) has received European Medicines Agency authorization to treat sinusoidal obstruction syndrome, an early complication after hematopoietic cell transplantation. DF has a recognized role as an endothelial protective agent, although its precise mechanism of action remains to be elucidated. The aim of the present study was to investigate the interaction of DF with endothelial cells (ECs). A human hepatic EC line was exposed to different DF concentrations, previously labeled. Using inhibitory assays and flow cytometry techniques along with confocal microscopy, we explored: DF-EC interaction, endocytic pathways, and internalization kinetics. Moreover, we evaluated the potential role of adenosine receptors in DF-EC interaction and if DF effects on endothelium were dependent of its internalization. Confocal microscopy showed interaction of DF with EC membranes followed by internalization, though DF did not reach the cell nucleus even after 24 hours. Flow cytometry revealed concentration, temperature, and time dependent uptake of DF in 2 EC models but not in other cell types. Moreover, inhibitory assays indicated that entrance of DF into ECs occurs primarily through macropinocytosis. Our experimental approach did not show any evidence of the involvement of adenosine receptors in DF-EC interaction. The antiinflammatory and antioxidant properties of DF seem to be caused by the interaction of the drug with the cell membrane. Our findings contribute to a better understanding of the precise mechanisms of action of DF as a therapeutic and potential preventive agent on the endothelial damage underlying different pathologic situations. •Specific interaction of DF with EC membranes is followed by its internalization mainly through macropinocytic mechanisms.•DF attachment to the cell membrane is sufficient to perform its antiinflammatory and antioxidant effects on the endothelium.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26755708</pmid><doi>10.1182/blood-2015-10-676114</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6658-0381</orcidid><orcidid>https://orcid.org/0000-0002-3261-6577</orcidid><orcidid>https://orcid.org/0000-0003-1122-0052</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2016-03, Vol.127 (13), p.1719-1727
issn 0006-4971
1528-0020
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4817313
source ScienceDirect®
subjects Anti-Inflammatory Agents - pharmacokinetics
Antioxidants - pharmacokinetics
Cell Membrane - drug effects
Cell Membrane - metabolism
Cells, Cultured
Dose-Response Relationship, Drug
Human Umbilical Vein Endothelial Cells - drug effects
Human Umbilical Vein Endothelial Cells - metabolism
Humans
Inflammation - pathology
Inflammation - prevention & control
Nitric Oxide Synthase Type III - metabolism
Pinocytosis - drug effects
Polydeoxyribonucleotides - pharmacokinetics
Temperature
Time Factors
Vascular Biology
title What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A54%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20is%20going%20on%20between%20defibrotide%20and%20endothelial%20cells?%20Snapshots%20reveal%20the%20hot%20spots%20of%20their%20romance&rft.jtitle=Blood&rft.au=Palomo,%20Marta&rft.date=2016-03-31&rft.volume=127&rft.issue=13&rft.spage=1719&rft.epage=1727&rft.pages=1719-1727&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2015-10-676114&rft_dat=%3Celsevier_pubme%3ES0006497120303049%3C/elsevier_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c463t-d162c24fe2c553e964b81ce31560982fa81a7c62a3a40e4b2728f19a310c94263%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/26755708&rfr_iscdi=true